Kala Pharmaceuticals
Kala Pharmaceuticals initiates Phase 2 trial to evaluate LE-MPP (KPI-121) in patients with retinal vein occlusion and diabetic macular edema. (read more)
Kala Pharmaceuticals initiates Phase 2 trial to evaluate LE-MPP (KPI-121) in patients with retinal vein occlusion and diabetic macular edema. (read more)